NAV

Avasopasem manganese

This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Avasopasem manganese
DrugBank Accession Number
DB16354
Background

Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.1,2This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19.

Type
Small Molecule
Groups
Investigational
Structure
MOL SDF PDB SMILES InChI
Similar Structures
Weight
Average: 518.83
Monoisotopic: 517.134397
Chemical Formula
C21H35Cl3MnN5
Synonyms
  • Avasopasem manganese
External IDs
  • GC-4419
  • GC4419
  • M-40419
  • SC-72325A

Ph值armacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Ph值armacodynamics

Not Available

Mechanism of action

Avasopasem manganese is a superoxide dismutase mimetic that rapidly and selectively converts superoxide to hydrogen peroxide and oxygen in order to protect normal tissue from radiation therapy-induced damage.1This drug is currently being investigated against oral mucositis, esophagitis, and COVID-19.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Ph值armacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
剂量、剂型、贴标机、给药途径nd marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
Ingredient UNII CAS InChI Key
Avasopasem manganese Not Available Not Available Not applicable

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
EY1WA413UL
CAS number
435327-40-5
InChI Key
WXEMWBBXVXHEPU-NDOCQCNASA-L
InChI
InChI=1S/C21H35N5.2ClH.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;;;/h5-7,18-25H,1-4,8-15H2;2*1H;/q;;;+2/p-2/t18-,19-,20-,21-;;;/m0.../s1
IUPAC Name
SMILES
[Cl-].[Cl-].[Mn++].C1CC[C@@H]2NCC3=CC=CC(CN[C@H]4CCCC[C@@H]4NCCN[C@H]2C1)=N3

References

一般引用
  1. GlobeNewswire: Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin [Link]
  2. Galera Therapeutics: AVASOPASEM (GC4419) [Link]
ChemSpider
32699517

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Ph值ase Status Purpose Conditions Count
2 Completed Prevention Head And Neck Cancer/Oral Mucositis 1
2 Completed Supportive Care Radiation Mucositis 1
2 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) 1
1 Completed Supportive Care Oropharyngeal Squamous Cell Carcinoma/Squamous Cell Carcinoma of the Oral Cavity 1
1 Completed Treatment Healthy Subjects (HS) 5
1 Completed Treatment Impaired Renal Function 1
1, 2 Completed Treatment Pancreatic Cancer/Stereotactic Body Radiation Therapy (SBRT) 1

Ph值armacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Property Value Source
Water Solubility 0.0124 mg/mL ALOGPS
logP 0.9 ALOGPS
logS -4.5 ALOGPS
Rule of Five No Chemaxon
Ghose Filter No Chemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 16, 2020 16:49 / Updated at May 22, 2021 06:08